PL374574A1 - gM-negatywne mutanty EHV bez elementów heterologicznych - Google Patents

gM-negatywne mutanty EHV bez elementów heterologicznych

Info

Publication number
PL374574A1
PL374574A1 PL03374574A PL37457403A PL374574A1 PL 374574 A1 PL374574 A1 PL 374574A1 PL 03374574 A PL03374574 A PL 03374574A PL 37457403 A PL37457403 A PL 37457403A PL 374574 A1 PL374574 A1 PL 374574A1
Authority
PL
Poland
Prior art keywords
ehv
heterologous elements
mutants
viruses
negative ehv
Prior art date
Application number
PL03374574A
Other languages
English (en)
Other versions
PL208225B1 (pl
Inventor
Antonie Neubauer
Christina Ziegler
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PL374574A1 publication Critical patent/PL374574A1/pl
Publication of PL208225B1 publication Critical patent/PL208225B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL374574A 2002-07-19 2003-07-16 Koński herpeswirus (EHV), zastosowanie EHV, sposób otrzymywania rekombinowanego EHV i preparat szczepionki oraz linia komórkowa PL208225B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002133064 DE10233064A1 (de) 2002-07-19 2002-07-19 gM-negative EHV-Mutanten ohne heterologe Elemente

Publications (2)

Publication Number Publication Date
PL374574A1 true PL374574A1 (pl) 2005-10-31
PL208225B1 PL208225B1 (pl) 2011-04-29

Family

ID=30010261

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374574A PL208225B1 (pl) 2002-07-19 2003-07-16 Koński herpeswirus (EHV), zastosowanie EHV, sposób otrzymywania rekombinowanego EHV i preparat szczepionki oraz linia komórkowa

Country Status (17)

Country Link
EP (1) EP1539808B1 (pl)
JP (2) JP4688491B2 (pl)
KR (2) KR101111998B1 (pl)
CN (4) CN101711864A (pl)
AT (1) ATE427958T1 (pl)
AU (1) AU2003258517B2 (pl)
BR (1) BR0312787A (pl)
CA (1) CA2493406C (pl)
CY (1) CY1109206T1 (pl)
DE (2) DE10233064A1 (pl)
DK (1) DK1539808T3 (pl)
ES (1) ES2324406T3 (pl)
MX (1) MXPA05000592A (pl)
PL (1) PL208225B1 (pl)
PT (1) PT1539808E (pl)
SI (1) SI1539808T1 (pl)
WO (1) WO2004009802A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
CN101926560A (zh) * 2010-08-31 2010-12-29 苏州星岛金属制品有限公司 可伸缩的凳子
NZ751966A (en) * 2016-09-20 2023-03-31 Boehringer Ingelheim Vetmedica Gmbh New promoters
US20250114447A1 (en) 2021-08-06 2025-04-10 Intervet Inc. Vaccine for equine herpesvirus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants

Also Published As

Publication number Publication date
DE10233064A1 (de) 2004-02-05
CN101711864A (zh) 2010-05-26
CA2493406C (en) 2013-02-26
AU2003258517B2 (en) 2009-05-07
EP1539808A2 (en) 2005-06-15
WO2004009802A2 (en) 2004-01-29
JP2010057512A (ja) 2010-03-18
WO2004009802A3 (en) 2005-04-21
DK1539808T3 (da) 2009-07-27
CY1109206T1 (el) 2014-07-02
CN101712949A (zh) 2010-05-26
ATE427958T1 (de) 2009-04-15
BR0312787A (pt) 2005-05-03
CN1668736A (zh) 2005-09-14
CN101712949B (zh) 2013-07-03
KR101111998B1 (ko) 2012-02-15
MXPA05000592A (es) 2005-04-28
JP5469444B2 (ja) 2014-04-16
CA2493406A1 (en) 2004-01-29
KR101167576B1 (ko) 2012-08-01
DE60327082D1 (de) 2009-05-20
SI1539808T1 (sl) 2009-08-31
PT1539808E (pt) 2009-05-21
CN102978168A (zh) 2013-03-20
JP2005532819A (ja) 2005-11-04
EP1539808B1 (en) 2009-04-08
ES2324406T3 (es) 2009-08-06
JP4688491B2 (ja) 2011-05-25
PL208225B1 (pl) 2011-04-29
AU2003258517A1 (en) 2004-02-09
KR20050055689A (ko) 2005-06-13
KR20110007629A (ko) 2011-01-24

Similar Documents

Publication Publication Date Title
AU2002305450A1 (en) Proteomimetic compounds and methods
MXPA03000627A (es) Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
UA101597C2 (uk) Псевдоінфекційний флавівірус та його використання
AU6304394A (en) Urethanes and ureas that induce cytokine production
MXPA05005202A (es) Vacuna.
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
DE69732712D1 (de) INHIBITOREN DES INTERLEUKIN-1beta KONVERTIERENDEN ENZYMS
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE69925581D1 (de) 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
WO2005035558A3 (en) Piscirickettsia salmonis antigens and use thereof
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
PT1539808E (pt) Mutantes de ehv gm-negativos sem elementos heterólogos
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
FR2828405B1 (fr) Vaccin anti-coronavirus
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
AR040601A1 (es) Mutantes ehv negativos de gm sin elementos heterologos
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
PL1949913T3 (pl) Immunostymulująca kombinacja do profilaktyki i leczenia wirusowego zapalenia wątroby typu c
AU2003251729A1 (en) Use of antibodies against flt-1 for the treatment of osteoporosis
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
WO2005056051A3 (en) Hepatitis b vaccines and compositions